Refractory status epilepticus: RSE is defined as SE that continues despite appropriate anticonvulsant treatment with benzodiazepines, phenobarbital, or valproate for up to 2 h, usually requiring general anesthesia. 4 Super-refractory status epilepticus (SRSE) is defined as SE that continues for 24 h or more after the onset of anesthesia, including those cases in which SE recurs on the reduction or withdrawal of anesthesia. 4 Pre-existing epilepsy: Holtkamp et al. 3 proposed that preexisting epilepsy is defined as two or more unprovoked epileptic seizures that occurred more than 4 weeks before the onset of SE. Post-status epilepticus symptomatic epilepsy: This condition is established in patients without pre-existing epilepsy, with the occurrence of at least one unprovoked epileptic seizure occurring not earlier than 4 weeks after termination of SE. 3 Encephalitis: Encephalitis is defined as encephalopathy (depressed or altered level of consciousness lasting for over 24 h, with mental and behavioral abnormalities), and one or more of the following clinical or diagnostic findings: fever, focal neurologic findings, seizures, cerebrospinal fluid (CSF) alteration, electroencephalographic (EEG) abnormality, or neuroimaging alteration, excluding systematic autoimmune disorders, metabolic encephalopathy, and intoxication by screening tests. 6 
Patients and clinical data
Consecutive cases of SRSE patients aged 16 years or older, who were admitted to the NICU or Neurology Department of West China Hospital, Sichuan University, between January 2010 and August 2013, were retrospectively included for this study. The NICU and the Epilepsy Center in West China Hospital are the largest centers in West China. The study was approved by the local ethics committee of the West China Hospital, Sichuan University. Informed consent was obtained from each patient or the legal guardians.
Data were retrospectively collated with a structured data collection table by reviewing the medical charts. Demographic data (age and sex), clinical features including seizure type, main tests and examinations, past history and etiology, management of SRSE, duration of anesthesia, length of stay in the NICU and in the hospital, and development of post-SE symptomatic epilepsy were analyzed. Outcome at discharge, at three-month and long-term follow-ups were analyzed and evaluated by the Glasgow Outcome Scale (GOS) following Legriel's study, 7 which were categorized as died (GOS score = 1), not improved (GOS score = 2), improved (GOS score = 3-4), and recovered to the baseline condition (GOS score = 5). For patients who lost to follow-up, outcome evaluated at the last evaluation on clinical outcome was taken for further analysis.
Statistical analysis
Statistical analysis was performed with SPSS (version 16.0). Descriptive summaries were reported as the median (range) or mean AE SD for continuous variables and as frequency for categorical variables. The Wilcoxon signed-rank test was used for paired comparison of two time-point outcomes, and Fisher's exact test was used for categorical variables, accounting for the relative small sample size. All tests were two-sided, and the significance was set at P < 0.05.
Results

Clinical features
Demographic data and etiologies
Thirteen patients fulfilled the diagnostic criteria for SRSE were included. Eight of the thirteen patients (61.5%) were males.
Nine of the thirteen (69.2%) were diagnosed with encephalitis, two (15.4%) with pre-existing epilepsy without appropriate antiepileptic therapy, one (7.7%) with stroke sequelae and one (7.7%) with hypoxic encephalopathy combined with metabolic acidosis.
The median age of the encephalitis subgroup was 23 years (range 16-60), while the age of the four patients with other etiologies ranged from 60 to 81 years. Young patients with encephalitis were the largest subgroup (8 patients, 61.5% of the whole SRSE patient group).
Clinical manifestations
In the subgroup of patients with encephalitis, the main clinical manifestations were fever, altered level of consciousness, mental and behavioral abnormalities, focal neurologic deficits and seizures. In terms of seizure type, nine patients initially displayed intermittent generalized-convulsive seizures (GCS), with the frequency and duration of seizures gradually increasing until SE finally became established. Two patients developed generalized convulsive SE (GCSE) at the time of onset, and two patients initially presented with GCS followed by subtle SE. Four patients had complex partial SE (CPSE) and one patient myoclonus SE.
In the pre-existing epilepsy subgroup, one patient had two separate seizures (six and three months prior) without anti-epileptic treatment until the SE incident. Another patient took antiepileptic drugs (AEDs) irregularly. The patient with a stroke history presented with new onset refractory status epilepticus (NORSE). The patient with encephalopathy had severe pulmonary infections (bacteria and fungi) eliciting respiratory failure and secondary metabolic acidosis that may have triggered SE.
Tests and examinations
Continuous video-EEG monitoring was initiated while patients were in coma, or during the titration or tapering process of anesthetic agents with the goal of achieving cessation of electrographic seizures or burst suppression. All patients underwent neuroimaging involving CT or MRI, systematic immunologic antibody tests, such as anti-nuclear antibody spectrum (ANAs) and anti-neutrophil cytoplasmic antibodies (ANCA), thyroid hormone tests and oncological assessments i.e., serological tumor markers, thoracic and abdominal tumor screening by imaging investigations. All patients who were suspected to have encephalitis received a CSF test and serologic test of immunoglobin-M (IgM) against Toxoplasma, Rubella, Cytomegalovirus, and Herpes simplex virus (abbreviated as TORCH). Moreover, from October 2011, antibodies for the N-methyl-D-aspartate receptor (NMDAR) in the CSF and serum were tested in patients with suspected anti-NMDAR encephalitis.
Among the nine patients diagnosed with encephalitis, neuroimaging examinations showed abnormalities in two patients on admission, in three further patients imaging was normal at admission but turned abnormal when rechecked during the treatment. Four patients had no abnormal features relevant to encephalitis on brain imaging. CSF tests revealed mild pleocytosis in five patients, mild protein increase in one, intracranial hypertension in two and no abnormality in one for whom the lumbar puncture was not rechecked because of contraindications. A causative agent was identified in two of the nine patients (22.2%) with encephalitis (one was Toxoplasma-IgM, the other cytomegalovirus-IgM positive). The NMDAR antibodies in the CSF and serum were tested for one patient, a young female who presented with psychosis, unresponsiveness and seizures. However, the results were negative. In addition, all patients had negative systematic immunologic antibody tests, thyroid hormone tests and oncological assessments. None of the patients showed extreme delta brush (EDB) which may be a unique EEG pattern in adult patients with anti-NMDAR encephalitis. 8 
Complications
All patients had medical complications during hospitalization. All thirteen patients had pneumonia, five had hypoproteinemia, four had urinary tract infection, four had electrolyte disturbance, two had deep-veinous thrombosis, two had infectious shock, two had decubitus ulcer, one had metabolic acidosis, one had hepatic function impairment, one had sepsis, one had myoglobinuria, one had hypotension and one had pulmonary fungal infection.
Detailed information for each patient is listed in Table 1 3.2. Management of SRSE Management of SRSE was mainly conducted in accordance to the guidelines for SE (2012) and other literatures for RSE. 4, [9] [10] [11] Continuous intravenous anesthetic agents, including midazolam, diazepam and propofol, were administered either combined or alone. The anesthetics were tapered after the clinical seizure or electrographic seizure had been controlled for 24-48 h, and reestablished if recurred. 4 The duration of anesthetic cycles increased gradually over time up to several days, and the weaning speed slowed down. Table 2 .
3.3. Outcome 3.3.1. Outcome at discharge Two patients (15.4%) died in the hospital (GOS score = 1), whereas 11 patients (84.6%) were discharged. Thus, seven patients needed further therapy (GOS score = 2) and 4 patients could return home with oral AEDs (GOS score = 3-5). The data about distribution of GOS outcomes are show in Fig. 1 The mortality in older patients (!60 yrs, 3/5, 60%) and patients with multiple complications (!3 types, 4/6, 66.7%) was higher compared with younger patients (<60 yrs, 1/6, 16.7%) and patients with less complications (<3 types, 0/5, 0%). However, these differences were not significant (both P > 0.05). The mortality was not affected by recognition of the etiology of encephalitis (odds ratio = 0.4, P = 0.576). The mean GOS score for survivors was 2.7 AE 1.1 at discharge. Table 3 . 
Outcome at three-month and long-term follow-ups
After being discharged from the hospital, two patients with seizure relapse died 24 h after ceasing therapy, whereas five patients continued to receive treatment in a local hospital for weeks or months. At the three-month follow-up, two patients (seizure cessation; !60 yrs) died because of fatal systematic complications. For the seven patients who survived until the time of follow-up, the mean GOS score significantly increased from Abbreviations: GOS, Glasgow Outcome Scale; NICU, neurologic intensive care unit; SE, status epilepticus; d, day; m, month. a The patient was lost to follow-up, so the last evaluation of clinical outcome was taken for analysis. b The patient gave up therapy and died 24 h after discharge. c The patient was seizure controlled and awake but later died of systematic complications. d The patient had a long course of consciousness disorder and recurrent seizures before this episode of SE, combined with severe systematic complication; she died of central respiratory and circulatory failure. e The patient died of multi-organ failure. Fig. 1 . Overall outcome at discharge, at three-month and long-term follow-ups. GOS score = 1: died; GOS score = 2: not improved, GOS score = 3-4: improved, GOS score = 5: recovered to the baseline condition; GOS, Glasgow Outcome Scale.
3.1 AE 1.2 at discharge to 4.1 AE 1.2 at three-month follow-up (P = 0.038).
At the three-month follow-up, a higher proportion of patients requiring a longer period of anesthesia (2/3 with >4 d, versus 1/4 with 4 d) and a higher proportion of those with encephalitis (3/5 versus 0/2 of non-encephalitis) had not fully recovered (GOS score = 2 to 4). Nonetheless, the differences were not significant (both P > 0.05). Moreover, among the six survivors without preexisting epilepsy, three patients (50%) developed post-SE symptomatic epilepsy.
At the long-term follow-up (median 17 months, range five months to 44 months), the mean GOS score was 4.6 AE 0.8 versus 4.1 AE 1.2 at three-month follow-up (P = 0.083).
Similarly, at the long-term follow-up, there was higher proportion of patients who had required longer anesthesia (2/3, with >4 d, versus 0/4, with 4 d) or who had experienced encephalitis (2/5 versus 0/2 of non-encephalitis patients) had not fully recovered. The differences were still not significant (both P > 0.05). Moreover, at long-term follow-up, the two patients with positive neuroimaging findings had poorer functional outcome with a GOS score of 3 or 4, compared with other five patients all with GOS score of 5.
The detailed data are presented in Table 3 and Fig. 1 .
Discussion
Encephalitis is the most common etiology (69.2%) in the present 13 SRSE patients from West China, but it accounted for a lower proportion of the RSE (22.2%) and non-refractory SE (NRSE; 4.3%) than in a previous study. 3 Other etiologies included pre-existing epilepsy without appropriate antiepileptic treatment, stroke sequelae and encephalopathy. In this series of SRSE, encephalitis was the primary cause and mainly occurred in young patients, which is consistent with the study of Holtkamp about malignant SE (defined as recurring SE within 5 d after tapering of anesthetic).
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Pre-existing epilepsy is a minor entity that is primarily associated with NRSE. 3 As proposed by the California Encephalitis Project (CEP), the definition of encephalitis includes infectious, noninfectious, and unknown etiologies. The relationship between encephalitis and identified pathogen is ranked into confirmed, probable, and possible causes. 6 In our series, nine patients were clinically diagnosed with encephalitis, among whom only two patients (22.2%) were identified with a possible infectious etiology. Nevertheless, anti-NMDAR encephalitis, which has been reported to surpass the viral etiologies, 13 was not observed based on clinical signs, symptoms, and ancillary tests. The findings from epidemiological studies suggested that the majority of cases are still of unknown etiology. 6, 14 The present study indicated the in-hospital mortality was 15.4%, and the three-month mortality was 36.4% (except for two patients who gave up therapy). These findings indicate that older patients (!60 yrs) and patients with multiple complications tend to have a higher risk of death, whereas an etiology of encephalitis has no effect on mortality. A recent review identified age and etiology as the principal independent outcome predictors of RSE. 11 However, the choice of anesthetic agents is independent of mortality. 2, 15 No comparative study about the appropriate AED regimens and optimal immunotherapy is currently available. 4 Eleven patients were discharged from the hospital with a long period of stay in the NICU or in the hospital. Seven of these 11 patients at discharge were in critical condition with seizure recurrence or consciousness disorder. Patients with prolonged RSE were more severely disabled than those with RSE at hospital discharge. 12 Pneumonia was the first prevalent complication in this series. A previous study indicated that pneumonia and prolonged mechanical ventilation are related to poor outcomes in RSE. 16 At long-term follow-up, two patients improved but still had neurologic deficits (18.2%), while 5 patients recovered to baseline condition (45.5%). We observed that a longer duration of needed anesthesia, etiology of encephalitis, and positive neuroimaging findings may result in a tendency of more severe neurologic sequelae, but the deficit gradually ameliorated over time. Due to the small number of patients, we cannot state with certainty whether these factors can affect the outcome of SRSE. A prior study on RSE also supported that longer duration of anesthesia required to achieve control of SE signifies worse functional outcome. 16 A study of prolonged SE supported that surviving patients have poor functional outcome at hospital discharge but return to good cognitive and functional status over time. 17 Another report suggested the use of aggressive therapy in prolonged RSE if an MRI remained normal. 18 The long-term outcome of this series (45.5% recovered) is more favorable than the review of outcomes in RSE and SRSE (35% recovered) by Shorvon and Ferlisi. 19 Therefore,
we recommend the continuation of aggressive anesthesia and support treatment in young patients without fatal systematic complications, particularly without responsible lesions on neuroimaging findings.
In our study, 50% of survivors developed symptomatic epilepsy post-SE. In a cohort study, symptomatic epilepsy developed in significantly more RSE patients (87.5%) than non-refractory SE patients (22.2%). 3 The current study probably underestimated the frequency because of the shorter follow-up and limited number of patients. However, it is still controversial that symptomatic epilepsy develops due to SE itself or underlying etiology. This report is limited by the small number of patients, a retrospective and descriptive study design, which did not allow the drawing of firm conclusions about the possible predictors of SRSE and clinical outcome. Another limitation is the insufficiency of the detection methods. The causative agents were not tested by agentspecific PCR or cultured pathogens, and NMDAR antibodies were tested in one patient only who was suspected to have autoimmune encephalitis. The other eight patients were clinically ruled out of having autoimmune encephalitis because of the absence of typical clinical and epidemiological features. For instance, anti-NMDAR encephalitis is more common in young adult females and is characterized by psychosis, decreased consciousness, seizures, language dysfunction, dyskinesia and a unique EEG pattern of EDB. 8, 13, 20 To our knowledge, this study is the first series report based on the definition of SRSE with regard to the clinical features, management, and outcome of SRSE in China. In further studies, we will exert more efforts to establish a database in China regarding the clinical features and outcome of patients with SRSE, which will then estimate the therapeutic regimen, predictors on outcome, and possible impacts of SRSE.
Conclusion
Our results indicate that encephalitis is the primary cause of SRSE in West Chinese adults, and the typical patient susceptible to develop SRSE is young patient with encephalitis. The factors of old age and multiple complications tend to increase the risk of death. Most patients can survive with aggressive therapy. For young SRSE patients, survival with a meaningful functional recovery over a long duration is possible.
